|
Apr 08, 2021
|
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients
|
|
|
Apr 05, 2021
|
GBT Announces New Employment Inducement Grants
|
|
|
Mar 18, 2021
|
GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors
|
|
|
Mar 16, 2021
|
GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.
|
|
|
Mar 08, 2021
|
GBT Announces New Employment Inducement Grants
|
|
|
Mar 02, 2021
|
GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease Community
|
|
|
Mar 02, 2021
|
GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
|
|
|
Feb 24, 2021
|
GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
|
|
|
Feb 19, 2021
|
GBT Announces Participation in Upcoming Investor Conferences
|
|
|
Feb 17, 2021
|
GBT to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021
|
|
|
Feb 05, 2021
|
GBT Announces New Employment Inducement Grants
|
|
|
Feb 04, 2021
|
GBT Initiates Expanded Access Protocol for Oxbryta® (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States
|
|
|
Jan 27, 2021
|
European Medicines Agency Accepts GBT’s Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease
|
|
|
Jan 07, 2021
|
GBT Announces New Employment Inducement Grants
|
|
|
Jan 05, 2021
|
GBT Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference
|
|